Human Immunoglobulin Market Size, Share, Analysis, Industry Report and Forecast 2021-2027

The global human immunoglobulin market is expected to grow at a significant CAGR during the forecast period (2021-2027). Immunoglobulin (also known as gamma globulin or immune globulin) is a plasma-derived protein. Antibodies that protect the body against illnesses are found in plasma made from donated human blood. Human body uses antibodies from other people's blood plasma to assist avoid disease when given an immunoglobulin. Even though immunolobulins are made from blood, they are purified to ensure that the individual who receives them is not infected. Immunoglobulins are designed to fight against certain diseases such as hepatitis, chickenpox, and measles. Antibodies, or immunoglobulins, are glycoprotein molecules generated by plasma cells (white blood cells). They play an important role in the immune response by detecting and attaching to certain antigens, such as bacteria and virus.

To Request a Sample of our Report on Human Immunoglobulin Market: https://www.omrglobal.com/request-sample/human-immunoglobulin-market

The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, Pfizer Inc. announced in February 2021 that the US Food and Drug Administration (FDA) had approved the supplemental Biologics License Application (sBLA) for PANZYGA (Immune Globulin Intravenous [Human] - ifas 10 percent Liquid Preparation) to treat adult patients with chronic inflammatory demyelinating polyneuropathy, a rare neurological disease of the peripheral nerves (CIDP). PANZYGA is the only intravenous immunoglobulin (IVIg) for CIDP that has two FDA-approved maintenance dose alternatives, making it easier for patients to satisfy their clinical demands.

PANZYGA can also be given at a rate of up to 12 mg/kg/min infusion. In December 2019- Grifols, one of a leading producer of plasma-derived medicines, announced the launch of XEMBIFY (immune globulin subcutaneous human-klhw), the company's first 20% subcutaneous immunoglobulin therapy for the treatment of patients 2 years and older with primary immunodeficiency (PI). XEMBIFY is a subcutaneous injection that has been shown to be safe, effective, and tolerable in the treatment of PI, which are rare and chronic genetic illnesses that affect people who are born with a defective or missing immune system. There are approximately 150,0001 people with PI who may benefit from IG treatment. XEMBIFY is a balanced formulation for the treatment of a wide variety of PI patients, including those with risk factors such as diabetes or cardiac impairment, and it adds to Grifols' growing IG portfolio for PI treatment. The US Food and Drug Administration (FDA) approved XEMBIFY in July 2019.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Route of Administration

· By Application

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: Baxter International Inc., Grifols S.A., and CSL Ltd., among others.

(Get 15% Discount on Buying this Report)

A full Report of Human Immunoglobulin Market is Available @ https://www.omrglobal.com/industry-reports/human-immunoglobulin-market

Global Human Immunoglobulin Market Report by Segment

By Route of Administration

• Intravenous (IV)

• Intramuscular

By Application

• Measles

• Infection Hepatitis

• Others

Global Human Immunoglobulin Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.